Journal article icon

Journal article

Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial

Abstract:

Purpose

The Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial of patients at high risk of vascular disease found that adding extended-release niacin-laropiprant to intensive statin-based LDL-lowering therapy had no benefit on cardiovascular outcomes. However, the trial also identified previously unrecognized serious adverse effects (including new-onset diabetes, bleeding, and infection). Our objective was to exp...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.clinthera.2019.06.012

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
ORCID:
0000-0003-0374-8519
Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
Clinical Therapeutics Journal website
Volume:
41
Issue:
9
Pages:
1767-1777
Publication date:
2019-08-22
Acceptance date:
2019-06-21
DOI:
EISSN:
1879-114X
ISSN:
0149-2918
Pmid:
31447131
Source identifiers:
1048697
Language:
English
Keywords:
Pubs id:
pubs:1048697
UUID:
uuid:8f1dc549-2a52-4a8b-8c4c-74231c802f7c
Local pid:
pubs:1048697
Deposit date:
2019-10-11

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP